We are monitoring the impact of COVID-19 on APAC Biopharmaceuticals Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 584
Share on
Share on

Asia Pacific Biopharmaceuticals Market Research Report – Segmented By Product Type, Therapeutic Type & Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Growth, Trends and Forecast (2021 to 2026)

Pulished: April, 2021
ID: 584
Pages: 145

APAC Biopharmaceuticals Market Size (2021 to 2026)

The size of the Asia Pacific Biopharmaceuticals Market is estimated to be worth USD 40.25 billion in 2021. The market is expected to be growing at a CAGR of 10.05% and reach USD 64.96 billion by 2026. The Asia Pacific is the third-largest biopharmaceuticals market in the world after North America and Europe. The primary driver for the pharmaceutical industry in this region is generics, aided by factors such as the aging population and the impending expiry of patented drugs.

Biopharmaceuticals are medical drugs that can either be produced by biotechnological techniques like recombinant DNA technology or transgenic plants and genetically modified animals. Various diseases such as cancer, diabetes, rheumatoid arthritis, cardiovascular diseases, and chronic renal failure are treated by biopharmaceutical drugs, which were non-curable with earlier molecular drugs.

Significant factors such as technological advancements in biopharmaceuticals, increasing geriatric population, increasing research and development investment, and rising incidences of chronic diseases propel market growth. Besides, biopharmaceuticals' ability to approach a specific target with high efficiency helps treat various chronic diseases and disorders.

However, the risk of side effects and the high cost of biopharmaceuticals are restraining the market's growth.

This research report on the Asia-Pacific biopharmaceuticals market has been segmented and sub-segmented into the following categories:

By Product Type: 

  • Monoclonal Antibodies (mAb)
  • Erythropoietin
  • Biotech Vaccines
  • Recombinant Human (RH) Insulin
  • Granulocyte Colony-stimulating Factor (G-CSF)
  • Interferon
  • Human Growth Hormones (HGH)

By Therapeutic Type: 

  • Neurology
  • Infectious Diseases
  • Diabetes
  • Oncology
  • Cardiovascular
  • Other Therapeutic Areas

By Country: 

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Regionally, The Chinese biopharmaceutical market is forecasted to lead the Asia Pacific market due to the highest population. The Chinese government is investing more in research and development, which is propelling market growth. In addition, there is a considerable increase in the FDI because of the low-cost labor and infrastructure. 

The Indian biopharmaceutical market is one of the leading markets in the world. It holds an essential position in the global market. India export around 80% of the anti-retroviral across the globe. The Indian government is investing more in the biopharma market. The biopharmaceutical market contributes up to 60% of the total income generated by the industries. India supplies 50% of the aggregate demand for vaccines required globally.

The biopharmaceutical market growth is comparatively good in Japan. There is a lot of research going on in the field of biopharma. In addition, the increasing scale of pharmaceutical companies is escalating the demand of the market. 

The biopharmaceutical market in Australia is currently growing at a high pace. The government is investing hugely in the biopharmaceutical market. There is an excellent opportunity for foreign investment in the market. Due to the impact of COVID-19, market growth is growing substantially. 

There is an excellent advancement in R&D in South Korea, which boosts the biopharmaceutical market growth in this country. In addition, many clinical trials are going on in South Korea and are to fuel the market's demand. 


A few of the promising companies operating in the APAC Biopharmaceuticals market profiled in this report are Merck & Co., Inc., F. Hoffmann-La Roche AG, Eli Lilly and Company, Inc., Sanofi, Amgen Inc., AbbVie Inc., Biogen Idec, Bayer AG, Johnson & Johnson Services, Pfizer, Inc. and Novartis AG.

1. Introduction                                 

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 New Developments                               

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 By Product Type                       

                                5.1.1 Monoclonal Antibodies (mAb)       

                                5.1.2 Erythropoietin       

                                5.1.3 Biotech Vaccines  

                                5.1.4 Recombinant Human (RH) Insulin 

                                5.1.5 Granulocyte colony-stimulating factor (G-CSF)       

                                5.1.6 Interferon               

                                5.1.7 Human growth hormones (HGH)  

                5.2 By Therapeutic Type                               

                                5.2.1 Neurology               

                                5.2.2 Infectious diseases              

                                5.2.3 Diabetes  

                                5.2.4 Oncology 

                                5.2.5 Cardiovascular       

                                5.2.6 Other Therapeutic Areas  

6. Geographical Analysis                                              

                6.3 Asia-Pacific                 

                                6.1 Introduction               

                                6.2 China             

                                6.3 India              

                                6.4 Japan            

                                6.5 South Korea               

                                6.6 Australia      

7. Strategic Analysis                                       

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8. Market Leaders' Analysis                                        

                8.1 Merck & Co.                               

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Strategic Evaluation and Operations            

                                8.1.4 Financial analysis  

                                8.1.5 Legal issues             

                                8.1.6 Recent Developments       

                                8.1.7 SWOT analysis       

                                8.1.8 Analyst View          

                8.2 F. Hoffmann-La Roche AG                    

                8.3 Eli Lilly and Company                              

                8.4 Sanofi                           

                8.5 Amgen Inc.                 

                8.6 AbbVie Inc.                 

                8.7 Biogen Idec                

                8.8 Bayer AG                     

                8.9 Johnson & Johnson Services                               

                8.10 Pfizer                          

                8.11 Novartis AG                             

9. Competitive Landscape                                           

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10. Expert Opinions                                        

                10.1 Market Outlook                     

                10.2 Investment Opportunities                 


                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Biopharmaceuticals market By Region, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific Monoclonal Antibodies (mAb) Market By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Erythropoietin Market By Region, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Biotech Vaccines Market By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Recombinant Human (RH) Insulin Market By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Granulocyte colony-stimulating factor (G-CSF) Market By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Interferon Market By Region, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Human growth hormones (HGH) Market By Region, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Neurology Market By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Infectious diseases Market By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Diabetes Market By Region, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Oncology Market By Region, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific Cardiovascular Market By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific Other Therapeutic Areas Market By Region, From 2021 to 2026 (USD Billion)
  17. China Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  18. China Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)
  19. India Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  20. India Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)
  21. Japan Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  22. Japan Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)
  23. South Korea Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  24. South Korea Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)
  25. Australia Biopharmaceuticals market By Product Type, From 2021 to 2026 (USD Billion)
  26. Australia Biopharmaceuticals market By Therapeutic Type, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports


$ 1234 3335

Click for Request Sample